Details for Patent: 10,709,691

Which drugs does patent 10,709,691 protect, and when does it expire?

Patent 10,709,691 protects ISTURISA and is included in one NDA.

This patent has thirty-five patent family members in twenty-eight countries.

Summary for Patent: 10,709,691

Title:	Pharmaceutical dosage forms
Abstract:	The present invention relates to pharmaceutical dosage forms for oral administration comprising the drug substance 4-[(5R)-6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl]-3-fluorobenzonitrile or any pharmaceutically acceptable salt thereof and to processes of making said solid pharmaceutical dosage forms.
Inventor(s):	Beato; Stefania (Basel, CH), Quinton; Peggy (Waldighoffen, FR)
Assignee:	RECORDATI AG (Baar, CH)
Application Number:	16/175,082
Patent Claim Types: see list of patent claims	Use; Dosage form;

Drugs Protected by US Patent 10,709,691

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Recordati Rare	ISTURISA	osilodrostat phosphate	TABLET;ORAL	212801-001	Mar 6, 2020		RX	Yes	No						CUSHING'S DISEASE
Recordati Rare	ISTURISA	osilodrostat phosphate	TABLET;ORAL	212801-002	Mar 6, 2020		RX	Yes	No						CUSHING'S DISEASE
Recordati Rare	ISTURISA	osilodrostat phosphate	TABLET;ORAL	212801-003	Mar 6, 2020		DISCN	Yes	No						CUSHING'S DISEASE

International Family Members for US Patent 10,709,691

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	101116
Australia	2015287336
Brazil	112016030243
Canada	2954393
Chile	2017000026